CureledgerCureledger

Blog

The case for patient-controlled rare disease data across science, policy, and the lived experience.

Featured

Vision

It is no longer good business to leave rare diseases behind

The math changed. The institutions that retool first capture leadership.

Read →

This week

Regulatory

Our FDA Comment: AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program

Cureledger's May 27, 2026 comment to Docket FDA-2026-N-4390: rare disease as the pilot's most generalizable use case, within-person variability as the decision-quality threshold, privacy for cohorts under 100, and data custody that outlives the sponsor.

Read →
Data Sovereignty

Preventing AI medicine's biggest trap for rare disease

Why AI drug discovery becomes extraction without ownership infrastructure.

Read →
The rare disease singularity
Vision

The rare disease singularity

Four capabilities converged. Cures are reachable.

Read →

Search articles

Browse by tag

Clear ×
VisionRegulatoryData SovereigntyUltra-rareAccelerating innovationEhlers-DanlosNewborn screeningCompanyHistoryPatient ExperienceScience & Data
Read all29 of 109 · Tag: Accelerating innovation
  1. May 7, 2026The speed thesis
  2. May 7, 2026The community review as clinical trial
  3. May 7, 2026The cure horizon
  4. May 7, 2026The acceleration equation
  5. May 7, 2026The rare disease data market
  6. May 7, 2026The provider discovery problem
  7. May 7, 2026The global natural history study
  8. May 7, 2026High consanguinity as research accelerator
  9. May 7, 2026The regulatory arbitrage opportunity
  10. May 7, 2026Rare disease as the proving ground
  11. May 7, 2026The real-time trial as default
  12. May 7, 2026The product review as outcomes data
  13. May 7, 2026The insurance argument that wins
  14. May 7, 2026The end of the diagnostic odyssey
  15. May 7, 2026The phenotype cloud
  16. May 7, 2026The incidental diagnosis cascade
  17. May 7, 2026Control data for the next cure
  18. May 7, 2026Cross-condition signal detection
  19. May 7, 2026From Orphan Drug to Platform Drug
  20. May 7, 2026How Data Cures Rare Disease
  21. May 7, 2026The Drug Made for One
  22. May 7, 2026What the Nurses' Health Study Built, and What Rare Disease Lacks
  23. May 7, 2026Sponsors Leave. Patients Don't.
  24. May 7, 2026The Economics of One
  25. May 7, 2026The N-of-1 Trial as Infrastructure
  26. May 7, 2026The Parent Scientist
  27. May 7, 2026The Time Value of Data
  28. May 7, 2026When Diagnostic Categories Dissolve
  29. May 7, 2026Why We Say Cure